Please enable JavaScript to continue using this application.

Compare $CADL vs $VXRT | Chartloom

Compare

$CADL vs $VXRT

Candel Therapeutics Inc · Vaxart Inc

CADL

Candel Therapeutics Inc

VXRT

Vaxart Inc

Compare $CADL vs $VXRT

Comparing Candel Therapeutics Inc and Vaxart Inc

CADLCandel Therapeutics Inc

VXRTVaxart Inc

CADLCandel Therapeutics Inc

Market cap

$728M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

82.7%

52W performance

57.8%

FCF yield

-7.9%

VXRTVaxart Inc

Market cap

$105M

P/E (TTM)

2.73x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

201.1%

YTD performance

19.2%

52W performance

26.5%

FCF yield

31.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CADL

VXRT

Detailed metrics comparison

CADL

Candel Therapeutics Inc

VXRT

Vaxart Inc

Market Cap

CADL$728M

VXRT$105M

Enterprise Value

CADL$575M

VXRT$62M

Price

CADL$9.94

VXRT$0.43

P/E Ratio

CADLN/A

VXRT2.73x

P/S Ratio

CADL6,281.93x

VXRT0.43x

EV/Sales

CADL5,042.14x

VXRT0.25x

EV/EBITDA

CADL0.00x

VXRT1.01x

P/B Ratio

CADL6.18x

VXRT1.27x

P/FCF Ratio

CADLN/A

VXRT3.15x

EV/FCF

CADL-10.02x

VXRT1.85x

PEG Ratio

CADLN/A

VXRTN/A

Forward P/E (NTM)

CADLN/A

VXRTN/A

Forward P/S (NTM)

CADLN/A

VXRTN/A

Revenue (TTM)

CADL$0

VXRT$243M

Revenue Growth (YoY)

CADLN/A

VXRT201.1%

Forward Rev Growth

CADL371.1%

VXRT-98.8%

Gross Margin (TTM)

CADL0.0%

VXRT100.0%

Operating Margin (TTM)

CADL0.0%

VXRT16.3%

EBITDA Margin (TTM)

CADL0.0%

VXRT18.8%

Net Margin (TTM)

CADL0.0%

VXRT15.9%

FCF Margin (TTM)

CADLN/A

VXRT13.7%

Net Income (TTM)

CADL$-89M

VXRT$39M

FCF (TTM)

CADL$-57M

VXRT$33M

EPS (TTM)

CADL-$1.19

VXRT$0.16

ROE (TTM)

CADL-8938.0%

VXRT53.0%

ROA (TTM)

CADL-5631.0%

VXRT20.8%

ROIC (TTM)

CADL-6512.0%

VXRT50.2%

Cash

CADL$202M

VXRT$48M

Debt

CADL$48M

VXRT$5M

Net Cash/Debt

CADL$154M

VXRT$43M

Current Ratio (TTM)

CADL16.09x

VXRT1.60x

Quick Ratio (TTM)

CADL15.89x

VXRT1.52x

Debt/Equity (TTM)

CADL0.38x

VXRT0.06x

Debt/Assets (TTM)

CADL0.0%

VXRT0.0%

Interest Coverage (TTM)

CADLN/A

VXRTN/A

Net Debt/EBITDA (TTM)

CADL0.00x

VXRT0.00x

Beta

CADL-0.28

VXRT1.23

52W Performance

CADL57.8%

VXRT26.5%

YTD Performance

CADL82.7%

VXRT19.2%

% from 52W High

CADL-29.0%

VXRT-48.6%

% from 52W Low

CADL128.5%

VXRT42.4%

Asset Turnover (TTM)

CADL0.00x

VXRT1.31x

FCF Yield (TTM)

CADL-7.9%

VXRT31.8%

Earnings Yield (TTM)

CADL-12.2%

VXRT36.7%

Dividend Yield (TTM)

CADLN/A

VXRTN/A

Rule of 40

CADL0.0

VXRT214.8

EV/GP/RG

CADLN/A

VXRTN/A

Ticker research

View CADL research View VXRT research

Metric	CADL Candel Therapeutics Inc	VXRT Vaxart Inc
Market & Valuation
Market Cap	$728M	$105M
Enterprise Value	$575M	$62M
Price	$9.94	$0.43
P/E Ratio	N/A	2.73x
P/S Ratio	6,281.93x	0.43x
EV/Sales	5,042.14x	0.25x
EV/EBITDA	0.00x	1.01x
P/B Ratio	6.18x	1.27x
P/FCF Ratio	N/A	3.15x
EV/FCF	-10.02x	1.85x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$243M
Revenue Growth (YoY)	N/A	201.1%
Forward Rev Growth	371.1%	-98.8%
Profitability
Gross Margin (TTM)	0.0%	100.0%
Operating Margin (TTM)	0.0%	16.3%
EBITDA Margin (TTM)	0.0%	18.8%
Net Margin (TTM)	0.0%	15.9%
FCF Margin (TTM)	N/A	13.7%
Net Income (TTM)	$-89M	$39M
FCF (TTM)	$-57M	$33M
EPS (TTM)	-$1.19	$0.16
ROE (TTM)	-8938.0%	53.0%
ROA (TTM)	-5631.0%	20.8%
ROIC (TTM)	-6512.0%	50.2%
Financial Health
Cash	$202M	$48M
Debt	$48M	$5M
Net Cash/Debt	$154M	$43M
Current Ratio (TTM)	16.09x	1.60x
Quick Ratio (TTM)	15.89x	1.52x
Debt/Equity (TTM)	0.38x	0.06x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	1.23
52W Performance	57.8%	26.5%
YTD Performance	82.7%	19.2%
% from 52W High	-29.0%	-48.6%
% from 52W Low	128.5%	42.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.31x
FCF Yield (TTM)	-7.9%	31.8%
Earnings Yield (TTM)	-12.2%	36.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	214.8
EV/GP/RG	N/A	N/A
Ticker research	View CADL research	View VXRT research

Valuation

P/E Ratio

VXRT

2.73x

P/S Ratio

VXRT

0.43x

CADL

6,281.93x

EV/FCF

CADL

-10.02x

VXRT

1.85x

Growth & revenue

Revenue Growth TTM

VXRT

201.1%

Forward Revenue Growth

CADL

371.1%

VXRT

-98.8%

Profitability & performance

Gross Margin

VXRT

100.0%

CADL

0.0%

ROE

VXRT

53.0%

CADL

-8938.0%

FCF Yield %

VXRT

31.8%

CADL

-7.9%

52-Week Performance

CADL

57.8%

VXRT

26.5%

Detailed metrics comparison

CADL

Candel Therapeutics Inc

VXRT

Vaxart Inc

Market Cap

CADL$728M

VXRT$105M

Enterprise Value

CADL$575M

VXRT$62M

Price

CADL$9.94

VXRT$0.43

P/E Ratio

CADLN/A

VXRT2.73x

P/S Ratio

CADL6,281.93x

VXRT0.43x

EV/Sales

CADL5,042.14x

VXRT0.25x

EV/EBITDA

CADL0.00x

VXRT1.01x

P/B Ratio

CADL6.18x

VXRT1.27x

P/FCF Ratio

CADLN/A

VXRT3.15x

EV/FCF

CADL-10.02x

VXRT1.85x

PEG Ratio

CADLN/A

VXRTN/A

Forward P/E (NTM)

CADLN/A

VXRTN/A

Forward P/S (NTM)

CADLN/A

VXRTN/A

Revenue (TTM)

CADL$0

VXRT$243M

Revenue Growth (YoY)

CADLN/A

VXRT201.1%

Forward Rev Growth

CADL371.1%

VXRT-98.8%

Gross Margin (TTM)

CADL0.0%

VXRT100.0%

Operating Margin (TTM)

CADL0.0%

VXRT16.3%

EBITDA Margin (TTM)

CADL0.0%

VXRT18.8%

Net Margin (TTM)

CADL0.0%

VXRT15.9%

FCF Margin (TTM)

CADLN/A

VXRT13.7%

Net Income (TTM)

CADL$-89M

VXRT$39M

FCF (TTM)

CADL$-57M

VXRT$33M

EPS (TTM)

CADL-$1.19

VXRT$0.16

ROE (TTM)

CADL-8938.0%

VXRT53.0%

ROA (TTM)

CADL-5631.0%

VXRT20.8%

ROIC (TTM)

CADL-6512.0%

VXRT50.2%

Cash

CADL$202M

VXRT$48M

Debt

CADL$48M

VXRT$5M

Net Cash/Debt

CADL$154M

VXRT$43M

Current Ratio (TTM)

CADL16.09x

VXRT1.60x

Quick Ratio (TTM)

CADL15.89x

VXRT1.52x

Debt/Equity (TTM)

CADL0.38x

VXRT0.06x

Debt/Assets (TTM)

CADL0.0%

VXRT0.0%

Interest Coverage (TTM)

CADLN/A

VXRTN/A

Net Debt/EBITDA (TTM)

CADL0.00x

VXRT0.00x

Beta

CADL-0.28

VXRT1.23

52W Performance

CADL57.8%

VXRT26.5%

YTD Performance

CADL82.7%

VXRT19.2%

% from 52W High

CADL-29.0%

VXRT-48.6%

% from 52W Low

CADL128.5%

VXRT42.4%

Asset Turnover (TTM)

CADL0.00x

VXRT1.31x

FCF Yield (TTM)

CADL-7.9%

VXRT31.8%

Earnings Yield (TTM)

CADL-12.2%

VXRT36.7%

Dividend Yield (TTM)

CADLN/A

VXRTN/A

Rule of 40

CADL0.0

VXRT214.8

EV/GP/RG

CADLN/A

VXRTN/A

Ticker research

View CADL research View VXRT research

Metric	CADL Candel Therapeutics Inc	VXRT Vaxart Inc
Market & Valuation
Market Cap	$728M	$105M
Enterprise Value	$575M	$62M
Price	$9.94	$0.43
P/E Ratio	N/A	2.73x
P/S Ratio	6,281.93x	0.43x
EV/Sales	5,042.14x	0.25x
EV/EBITDA	0.00x	1.01x
P/B Ratio	6.18x	1.27x
P/FCF Ratio	N/A	3.15x
EV/FCF	-10.02x	1.85x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$243M
Revenue Growth (YoY)	N/A	201.1%
Forward Rev Growth	371.1%	-98.8%
Profitability
Gross Margin (TTM)	0.0%	100.0%
Operating Margin (TTM)	0.0%	16.3%
EBITDA Margin (TTM)	0.0%	18.8%
Net Margin (TTM)	0.0%	15.9%
FCF Margin (TTM)	N/A	13.7%
Net Income (TTM)	$-89M	$39M
FCF (TTM)	$-57M	$33M
EPS (TTM)	-$1.19	$0.16
ROE (TTM)	-8938.0%	53.0%
ROA (TTM)	-5631.0%	20.8%
ROIC (TTM)	-6512.0%	50.2%
Financial Health
Cash	$202M	$48M
Debt	$48M	$5M
Net Cash/Debt	$154M	$43M
Current Ratio (TTM)	16.09x	1.60x
Quick Ratio (TTM)	15.89x	1.52x
Debt/Equity (TTM)	0.38x	0.06x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	1.23
52W Performance	57.8%	26.5%
YTD Performance	82.7%	19.2%
% from 52W High	-29.0%	-48.6%
% from 52W Low	128.5%	42.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	1.31x
FCF Yield (TTM)	-7.9%	31.8%
Earnings Yield (TTM)	-12.2%	36.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	214.8
EV/GP/RG	N/A	N/A
Ticker research	View CADL research	View VXRT research